← Back to home

TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA-REFRACTORY

Clinical trials for TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA-REFRACTORY explained in plain language.

Never miss a new study

Get alerted when new TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA-REFRACTORY trials appear

Sign up with your email to follow new studies for TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA-REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for patients where CAR-T falls short

Disease control Recruiting now

This early-stage study is testing a new two-drug combination for patients with B-cell lymphoma. It is for people whose cancer did not respond well enough to a powerful treatment called CAR-T therapy. The goal is to see if adding an oral drug (CC-99282) to an existing antibody dru…

Matched conditions: TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA-REFRACTORY

Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control

Last updated Mar 30, 2026 14:29 UTC

TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA-REFRACTORY

Get alerted when new TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA-REFRACTORY trials appear

New hope for patients where CAR-T falls short